Valuation: Vivoryon Therapeutics N.V.

Market Cap 35.54M 40.89M 33.18M 30.46M 57.43M 3.9B 58.43M 391M 153M 1.94B 154M 150M 6.41B P/E 2026 *
-3.75x
P/E 2027 * -3.87x
Enterprise Value 38.63M 44.45M 36.06M 33.11M 62.42M 4.24B 63.51M 425M 167M 2.11B 167M 163M 6.97B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
82.01%
Yield 2026 *
-
Yield 2027 * -
1 day-3.33%
1 week+0.87%
Current month-2.93%
1 month+6.42%
3 months-11.79%
6 months-20.00%
Current year-18.31%
1 week 1.1
Extreme 1.105
1.2
1 month 1.08
Extreme 1.085
1.5
Current year 1
Extreme 1
1.65
1 year 1
Extreme 1
1.84
3 years 0.41
Extreme 0.41
12.9
5 years 0.41
Extreme 0.41
22.58
10 years 0.41
Extreme 0.41
24.4
Manager TitleAgeSince
Chief Executive Officer 66 2023-08-13
Director of Finance/CFO - 2024-02-29
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 56 2006-12-31
Director/Board Member 66 2023-09-14
Director/Board Member 58 -
Date Insider Type Main position Quantity % Market Cap.
10/23/25 Free

Chief Operating Officer

20,000 0.0767%
10/23/25 Buy

Chief Executive Officer

135,000 0.5179%
10/23/25 Free 20,000 0.0767%
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%+0.87%-18.54%-90.71% 40.89M
-0.34%0.00%-0.95%+13.63% 48.22B
+1.69%+1.30%+400.94%+496.76% 38.79B
-1.98%-5.38%+25.78%+5.97% 38.41B
+1.09%-4.19%+4.04%+56.52% 34.88B
-2.41%+1.96%+11.68%+38.17% 29.19B
-0.10%-0.12%+31.88%+120.40% 16B
-1.01%-4.50% - - 16.05B
+1.59%+0.50%+3.49%+16.87% 13.53B
-1.91%-13.39%-5.28%-38.39% 12.22B
Average -0.64%-0.34%+50.34%+68.80% 24.73B
Weighted average by Cap. -0.28%+0.15%+75.53%+107.76%

Financials

2026 *2027 *
Net sales - -
Net income -8.71M -10.02M -8.13M -7.47M -14.08M -955M -14.32M -95.88M -37.55M -476M -37.64M -36.81M -1.57B -8.71M -10.02M -8.13M -7.47M -14.08M -955M -14.32M -95.88M -37.55M -476M -37.64M -36.81M -1.57B
Net Debt 3.09M 3.56M 2.88M 2.65M 4.99M 339M 5.08M 34.02M 13.32M 169M 13.35M 13.06M 557M 11.8M 13.58M 11.02M 10.11M 19.07M 1.29B 19.4M 130M 50.88M 645M 51M 49.87M 2.13B
Logo Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.
Employees
13
Date Price Change Volume
26-08-04 1.160 -3.33% 7,686
26-08-03 €1.200 +0.42% 15,597
26-07-31 €1.195 +4.82% 28,071
26-07-30 €1.140 -1.72% 34,431
26-07-29 €1.160 +0.87% 13,468
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.200EUR
Average target price
6.850EUR
Spread / Average Target
+470.83%

Annual profits - Rate of surprise